• 25 February 2020

    United Therapeutics’ Tyvaso meets goals in PH-ILD patients

    United Therapeutics has reported that the Tyvaso (treprostinil) inhalation solution met all primary and secondary endpoints in the Phase III INCREASE trial involving patients with pulmonary hypertension caused by interstitial...

Close
Close
Close

Go Top